Squamous Non-Small Cell Lung Cancer: Current and Emerging Treatment Options
Paul K. Paik(Memorial Sloan Kettering Cancer Center), Jonathan W. Riess(University of California Davis Medical Center), Howard West(Vyne Therapeutics (United States)), Jianjun Zhang(The University of Texas MD Anderson Cancer Center)
Cited by 2
Related Papers
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2019|1.7k
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease
|Annals of Neurology|1997|1.5k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k